Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 1 - Drugs for disorders of the alimentary tract or the digestive system
Patents for A61P 1 - Drugs for disorders of the alimentary tract or the digestive system (125,798)
04/2003
04/30/2003CN1413703A Compound stomach-ache capsule
04/30/2003CN1413697A Method for preparing Chinese medicine Liuwei Dihuang preparation
04/30/2003CN1413692A Medicin spray for treating throat disease and stomatopathy
04/30/2003CN1413690A Medicine for treating intestinal disease
04/30/2003CN1413688A Medicine for treating cholecystopathy
04/30/2003CN1413685A Medicine for treating throat disease and stomatopathy
04/30/2003CN1413684A Medicine for treating stomach disease
04/30/2003CN1413681A Medicine for treating stomach trouble
04/30/2003CN1413669A External used medicine for recurrent aphtha
04/30/2003CN1413666A Strong health-care food and its production method
04/30/2003CN1413663A Capsule for positive of hepatitis B transformation to negative
04/30/2003CN1413662A Decoction for positive reaction of hepatitis B transformation to negative
04/30/2003CN1413658A Chinese medicine powder combined with westem medicine for treating gastric ulcer and gastritis and preparation method
04/30/2003CN1413651A Pill capable of treating hepatogastric disease
04/30/2003CN1413648A Chinese medicine composite for treating vomiting and diarrhea and its preparation method
04/30/2003CN1413640A Chinese medicine composition for treating enteritis
04/30/2003CN1413632A Medicine usage of Chinese medicine composite
04/30/2003CN1413631A Medicine for treating stomach disease
04/30/2003CN1413629A Oral liquid for nourishing yin and warming yang
04/30/2003CN1413626A Pill for treating hepatitis B
04/30/2003CN1413620A Shugan Zhitong soft extract for treating hepatitis
04/30/2003CN1413606A Medicine for treatment of hepatitis
04/30/2003CN1413605A Soft capsule capable of removing human peculliar smell
04/30/2003CN1413596A Yoghurt containing ossein protein capsule, chewing tablet and its preparation method
04/30/2003CN1413595A Mineralized liquid for prevention of dental caries
04/30/2003CN1413589A Composition of paeoniflorin and albiflorin and its preparation method
04/30/2003CN1107061C Chemotaxis cell factor receptor-3 receptor antagonists
04/30/2003CN1107058C Subsitituted isoxazoles for treatment of inflammation
04/30/2003CN1106856C Medicine for treating hepatosis and its preparation method
04/30/2003CN1106843C Specific anti-dizziness drug and prescription thereof
04/30/2003CN1106838C Production process of bio-active forest frog's oviduct soft capsule
04/29/2003US6555710 Aminobenzophenones as inhibitors of IL-1 β and TNF-α
04/29/2003US6555700 1,3-propane diol esters and ethers and methods for their use in drug delivery
04/29/2003US6555651 Ligand binding site of rage and uses thereof
04/29/2003US6555575 Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of disease
04/29/2003US6555546 Use of 5HT3 antagonists for promoting intestinal lavage
04/29/2003US6555545 Adenosine, caffeine, and 8-styryl-1,3,7-alkyl xanthine derivatives as wound healing agents
04/29/2003US6555542 Sulfonamide lactam inhibitors of FXa and method
04/29/2003US6555531 Weight promoting composition, method, and product
04/29/2003US6555520 Nucleotide sequences coding polypeptide for use in the treatment of cell proliferative and immunologicval disorders
04/29/2003US6555518 2',2'-difluoronucleosides for suppressing rejection of transplants in mammals; for treatment of autoimmune diseases
04/29/2003US6555377 Process for production of mammalian cell lines
04/29/2003US6555141 L-ergothioneine, Milk thistle, and S-adenosylmethionine for the prevention, treatment and repair of liver damage
04/29/2003US6555137 Sucralfate-containing composition and process for the preparation thereof
04/29/2003US6555093 Composition for the treatment of halitosis
04/29/2003CA2078028C A tramadol n-oxide material, enantiomers and compositions thereof, and their use
04/25/2003CA2426925A1 Water-soluble liquid internal medicine
04/25/2003CA2409910A1 Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
04/25/2003CA2409552A1 Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
04/24/2003WO2003033720A2 Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
04/24/2003WO2003033681A2 Composition comprising a lactobacillus pentosus strain and uses thereof
04/24/2003WO2003033528A1 Cyclic peptides as g-protein-coupled receptor antagonists
04/24/2003WO2003033527A2 Cyclosporine analogue mixtures and their use as immunomodulating agents
04/24/2003WO2003033507A1 Benzylmalonic acid derivatives and proteasome inhibitors contaiing the same
04/24/2003WO2003033506A1 Aminoborane acid derivative and proteasome inhibitory drug containing the same
04/24/2003WO2003033502A1 Bicyclic oxopyridine and oxopyrimidine derivatives
04/24/2003WO2003033495A1 Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors
04/24/2003WO2003033486A1 Novel substituted 4-phenyl-4-[1h-imidazol-2-yl]-piperidine derivatives and their use as selective non-peptide delta opioid agonists
04/24/2003WO2003033483A1 Biphenylcarboxylic amide derivatives as p38 kinase inhibitors
04/24/2003WO2003033482A1 Oxadiazolyl-biphenylcarboxamides and their use as p38 kinase inhibitors
04/24/2003WO2003033481A1 Benzoxazine and benzothiazine derivatives and parmaceutical compositions containing them
04/24/2003WO2003033478A1 Alkynylated fused ring pyrimidine compounds as matrix metalloprotease-13 inhibitors
04/24/2003WO2003033472A1 Quinoline or quinazoline derivatives inhibiting auto- phosphorylation of fibroblast growth factor receptors
04/24/2003WO2003033470A1 Arylsulfanyl and heteroarylsulfanyl derivatives for treating pain
04/24/2003WO2003033466A1 Aralkyl-tetrahydro-pyridines, their preparation and pharmaceutical compositions containing same
04/24/2003WO2003033457A1 Biphenyl-derivatives as p38-kinase inhibitors
04/24/2003WO2003033456A1 NOVEL β-PHENYL-α-OXYSUBSTITUTED PROPIONIC DERIVATIVES: PROCESS FOR ITS PREPARATION AND THEIR USE IN THE PREPARATION OF PHARMACEUTICALLY IMPORTANT COMPOUNDS
04/24/2003WO2003033027A2 Dendrimers for use in targeted delivery
04/24/2003WO2003033010A1 Cyclosporin analogs for the treatment of autoimmune diseases
04/24/2003WO2003033004A1 Agents for treating inflammatory bowel diseases
04/24/2003WO2003033002A1 Intracellular calcium concentration increase inhibitors
04/24/2003WO2003032999A1 Alkyne matrix metalloproteinase inhibitors
04/24/2003WO2003032997A1 Pyrimidine derivatives, pharmaceutical agent containing said compounds, use and method for making same
04/24/2003WO2003032993A1 Use of phosphorodiesterase iv inhibitors
04/24/2003WO2003032990A2 Polymer conjugates of opioid antagonists
04/24/2003WO2003032989A1 1,4-disubstituted benzo-fused urea compounds as cytokine inhibitors
04/24/2003WO2003032987A1 2'-methyl-5'-(1,3,4-oxadiazol-2-yl)-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
04/24/2003WO2003032986A1 2' -methyl-5-(1,3,4-oxadiazol-2-yl)-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
04/24/2003WO2003032980A1 5'-carbamoyl-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
04/24/2003WO2003032971A1 5’-acylamino-1,1’-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
04/24/2003WO2003032970A1 5'-carbamoyl-2'-methyl-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
04/24/2003WO2003032966A1 Compositions for potentiating glutatthione
04/24/2003WO2003032965A2 Use of ace inhibitors for reducing type 2 diabetes in high risk patients
04/24/2003WO2003032964A2 Gap junctions and endothelial-derived hyperpolarizing factor (edhf)
04/24/2003WO2003032963A2 Method of reducing type 2 diabetes in high risk patients
04/24/2003WO2003032955A1 Highly compressible ethylcellulose for tableting
04/24/2003WO2003032953A1 Granules containing acid-unstable chemical in large amount
04/24/2003WO2003032952A1 Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for use in treatment of ulcerative colitis and crohn's disease
04/24/2003WO2003032920A2 Oligonucleotide modulation of cell adhesion
04/24/2003WO2003032918A2 Treatment of infectious disease using interleukin-1 beta converting enzyme (ice)/ced-3 family inhibitors
04/24/2003WO2003032916A2 Organosulfur inhibitors of tyrosine phosphatases
04/24/2003WO2003032735A1 Remodeling of tissues and organs
04/24/2003WO2003011265A3 5-aminolevulinic acid and esters, in combination with another phtosensitizer, as photosensitizing agents in photochemotherapy, and their uses in treating wounds
04/24/2003WO2003005964A3 Recombinant vsv for the treatment of tumor cells
04/24/2003WO2002098907A3 Cation conducting gabaa receptors and their use
04/24/2003WO2002098850A3 Chemical compounds and pharmaceutical compositions as cathepsin s inhibitors
04/24/2003WO2002088343A3 RECOMBINANT EXPRESSION OF hHBV REVERSE TRANSCRIPTASE (RT)
04/24/2003WO2002068406A3 Substituted amine derivatives and their use for the treatment of angiogenesis
04/24/2003WO2002064748A8 Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
04/24/2003WO2002057259A3 Pyrazole compounds useful as protein kinase inhibitors
1 ... 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 ... 1258